Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
According to Disc Medicine, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2022 the company had a P/S ratio of 0.00.
Year | P/S ratio |
---|---|
2023 | 0.00 |
2022 | 0.00 |
2021 | 0.00 |
2020 | 0.00 |